615 related articles for article (PubMed ID: 35406785)
41. New Horizons in cellular senescence for clinicians.
Witham MD; Granic A; Miwa S; Passos JF; Richardson GD; Sayer AA
Age Ageing; 2023 Jul; 52(7):. PubMed ID: 37466640
[TBL] [Abstract][Full Text] [Related]
42. Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span.
Robbins PD; Jurk D; Khosla S; Kirkland JL; LeBrasseur NK; Miller JD; Passos JF; Pignolo RJ; Tchkonia T; Niedernhofer LJ
Annu Rev Pharmacol Toxicol; 2021 Jan; 61():779-803. PubMed ID: 32997601
[TBL] [Abstract][Full Text] [Related]
43. Cellular senescence: a key therapeutic target in aging and diseases.
Zhang L; Pitcher LE; Yousefzadeh MJ; Niedernhofer LJ; Robbins PD; Zhu Y
J Clin Invest; 2022 Aug; 132(15):. PubMed ID: 35912854
[TBL] [Abstract][Full Text] [Related]
44. EA.hy926 Cells and HUVECs Share Similar Senescence Phenotypes but Respond Differently to the Senolytic Drug ABT-263.
Abdelgawad IY; Agostinucci K; Ismail SG; Grant MKO; Zordoky BN
Cells; 2022 Jun; 11(13):. PubMed ID: 35805077
[TBL] [Abstract][Full Text] [Related]
45. Senolytics and the compression of late-life mortality.
Kowald A; Kirkwood TBL
Exp Gerontol; 2021 Nov; 155():111588. PubMed ID: 34637949
[TBL] [Abstract][Full Text] [Related]
46. Translating the Biology of Aging into New Therapeutics for Alzheimer's Disease: Senolytics.
Riessland M; Orr ME
J Prev Alzheimers Dis; 2023; 10(4):633-646. PubMed ID: 37874084
[TBL] [Abstract][Full Text] [Related]
47. Rutin is a potent senomorphic agent to target senescent cells and can improve chemotherapeutic efficacy.
Liu H; Xu Q; Wufuer H; Li Z; Sun R; Jiang Z; Dou X; Fu Q; Campisi J; Sun Y
Aging Cell; 2024 Jan; 23(1):e13921. PubMed ID: 37475161
[TBL] [Abstract][Full Text] [Related]
48. Exploring the fuzzy border between senolytics and senomorphics with chemoinformatics and systems pharmacology.
Olascoaga-Del Angel KS; Gutierrez H; Königsberg M; Pérez-Villanueva J; López-Diazguerrero NE
Biogerontology; 2022 Aug; 23(4):453-471. PubMed ID: 35781578
[TBL] [Abstract][Full Text] [Related]
49. Biomolecular Evaluation of Piceatannol's Effects in Counteracting the Senescence of Mesenchymal Stromal Cells: A New Candidate for Senotherapeutics?
Alessio N; Squillaro T; Lettiero I; Galano G; De Rosa R; Peluso G; Galderisi U; Di Bernardo G
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769049
[TBL] [Abstract][Full Text] [Related]
50. Identification of resibufogenin, a component of toad venom, as a novel senolytic compound in vitro and for potential skin rejuvenation in male mice.
Takaya K; Asou T; Kishi K
Biogerontology; 2023 Dec; 24(6):889-900. PubMed ID: 37395866
[TBL] [Abstract][Full Text] [Related]
51. Cellular Senescence Contributes to Large Elastic Artery Stiffening and Endothelial Dysfunction With Aging: Amelioration With Senolytic Treatment.
Clayton ZS; Rossman MJ; Mahoney SA; Venkatasubramanian R; Maurer GS; Hutton DA; VanDongen NS; Greenberg NT; Longtine AG; Ludwig KR; Brunt VE; LaRocca TJ; Campisi J; Melov S; Seals DR
Hypertension; 2023 Oct; 80(10):2072-2087. PubMed ID: 37593877
[TBL] [Abstract][Full Text] [Related]
52. Eliminating senescent cells by white adipose tissue-targeted senotherapy alleviates age-related hepatic steatosis through decreasing lipolysis.
Tang Q; Xing X; Huang H; Yang J; Li M; Xu X; Gao X; Liang C; Tian W; Liao L
Geroscience; 2024 Jun; 46(3):3149-3167. PubMed ID: 38217637
[TBL] [Abstract][Full Text] [Related]
53. Looking for the philosopher's stone: Emerging approaches to target the hallmarks of aging in the skin.
Lemaitre JM
J Eur Acad Dermatol Venereol; 2024 Jul; 38 Suppl 4():5-14. PubMed ID: 38881451
[TBL] [Abstract][Full Text] [Related]
54. Treating Senescence like Cancer: Novel Perspectives in Senotherapy of Chronic Diseases.
Mongelli A; Atlante S; Barbi V; Bachetti T; Martelli F; Farsetti A; Gaetano C
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33121118
[TBL] [Abstract][Full Text] [Related]
55. Cellular Senescence in Human Skin Aging: Leveraging Senotherapeutics.
Wyles SP; Carruthers JD; Dashti P; Yu G; Yap JQ; Gingery A; Tchkonia T; Kirkland J
Gerontology; 2024; 70(1):7-14. PubMed ID: 37879300
[TBL] [Abstract][Full Text] [Related]
56. Targeting the microbiota-mitochondria crosstalk in neurodegeneration with senotherapeutics.
Homolak J
Adv Protein Chem Struct Biol; 2023; 136():339-383. PubMed ID: 37437983
[TBL] [Abstract][Full Text] [Related]
57. Bone-targeted delivery of senolytics to eliminate senescent cells increases bone formation in senile osteoporosis.
Xing X; Tang Q; Zou J; Huang H; Yang J; Gao X; Xu X; Ma S; Li M; Liang C; Tan L; Liao L; Tian W
Acta Biomater; 2023 Feb; 157():352-366. PubMed ID: 36470392
[TBL] [Abstract][Full Text] [Related]
58. Pharmacological Targeting of Senescence with Senolytics as a New Therapeutic Strategy for Neurodegeneration.
Richardson M; Richardson DR
Mol Pharmacol; 2024 Jan; 105(2):64-74. PubMed ID: 38164616
[TBL] [Abstract][Full Text] [Related]
59. The Differential Effect of Senolytics on SASP Cytokine Secretion and Regulation of EMT by CAFs.
Bogdanova DA; Kolosova ED; Pukhalskaia TV; Levchuk KA; Demidov ON; Belotserkovskaya EV
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612842
[TBL] [Abstract][Full Text] [Related]
60. Potential Use of Senolytics for Pharmacological Targeting of Precancerous Lesions.
Saleh T; Carpenter VJ
Mol Pharmacol; 2021 Dec; 100(6):580-587. PubMed ID: 34544896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
